Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recombinant Humanized Anti- PD-1 Monoclonal Antibody（SCT-I10A） in Patients With Advanced Solid Tumors or Lymphoma :a Phase Ⅰ, Open-label, Multicenter Study

NCT03821363 is registered in ClinicalTrials.gov with Sinocelltech Ltd. as lead sponsor.

NCT NCT03821363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03821363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recombinant Humanized Anti- PD-1 Monoclonal Antibody（SCT-I10A） in Patients With Advanced Solid Tumors or Lymphoma :a Phase Ⅰ, Open-label, Multicenter Study
Lead sponsor
Sinocelltech Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
December 13, 2018
Completion date
July 31, 2020
Enrollment
206 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors or lymphoma